Provided by Tiger Trade Technology Pte. Ltd.

Merck

145.37
+0.66000.46%
Volume:3.97M
Turnover:574.56M
Market Cap:358.65B
PE:114.21
High:145.89
Open:145.77
Low:143.82
Close:144.71
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.73
T/O Rate:0.16%
Dividend:3.36
Dividend Rate:2.31%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.55
PE(LYR):19.97

Loading ...

Sector Update: Healthcare Stocks Decline Premarket Wednesday

MT Newswires Live
·
Jul 15

Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions

MT Newswires Live
·
Jul 15

Merck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial

Market Focus
·
Jul 15

Merck to Unveil New HIV Pipeline Data at AIDS 2026, Featuring Daily, Weekly, and Monthly Regimens

Deep News
·
Jul 15

Merck Rises After Partner Kelun-biotech Reports Positive Keytruda Lung Cancer Study

Reuters
·
Jul 15

Merck Rises as Keytruda Meets Main Goal in Late-stage Uterine Cancer Trial

Reuters
·
Jul 15

Merck to present new data from research pipeline for HIV treatment, prevention

TIPRANKS
·
Jul 15

Merck Hosts Virtual HIV Investor Event Aug. 3 After AIDS 2026 Data Presentations

Reuters
·
Jul 15

Merck says Phase 3 KEYNOTE-C93 trial of Keytruda met primary endpoint

TIPRANKS
·
Jul 15

Merck Says Keytruda Monotherapy Improves PFS in Phase 3 Trial for Dmmr Endometrial Cancer

Reuters
·
Jul 15

Keytruda® (pembrolizumab) as Monotherapy Significantly Improved Progression-free Survival (pfs) in Certain Patients with Advanced or Recurrent Endometrial Cancer with Mismatch Repair Deficient (dmmr) Tumors Compared to Chemotherapy

THOMSON REUTERS
·
Jul 15

Merck & Co - Phase 3 Keynote-c93 Trial Meets Primary Endpoint of Progression-free Survival

THOMSON REUTERS
·
Jul 15

Merck & Co - Interim Analysis Shows Trend Toward Improved Os for Keytruda; Os Data not Mature

THOMSON REUTERS
·
Jul 15

Merck & Co - Keytruda Safety Profile Consistent with Previous Studies; no New Safety Signals Identified

THOMSON REUTERS
·
Jul 15

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Annexon Biosciences (ANNX) and Guardant Health (GH)

TIPRANKS
·
Jul 15

Zoetis Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 15

Movement Alert|Merck Drops 3.03% in Regular Trading, Trading at $120.42

Market Focus
·
Jul 15

Dow's 159-point Drop Led by Losses in Shares of IBM, Merck

Dow Jones
·
Jul 14

Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug

MT Newswires Live
·
Jul 14

Merck is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 13